ZYBERNO
Stock Report
Updated Sep 1, 2026

CARDIFF LEXINGTON CORPORATION (CDIX)

Healthcare • OTC

$0.20

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
CARDIFF LEXINGTON CORPORATION (CDIX) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,344.2%)
Debt-to-Equity (Solvency Risk):CRITICAL (13.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.4%)
Return on Capital (Capital Efficiency):CRITICAL (0.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CARDIFF LEXINGTON CORPORATION (CDIX) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.20
Market Cap:$3.05M

Valuation Multiples (3)

P/B Ratio:1.74x
P/S Ratio:0.30x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$27.43M
Ev Ebitda Ratio:581.77x

Price Action & Momentum (1)

% of 52-Week High:3.3%
B. Profitability Assessment

Margin Analysis (3)

Operating Margin Ttm:0.4%
Net Margin Ttm:-92.1%
Ebitda Margin:0.5%

TTM Performance (3)

Gross Margin Ttm:60.4%
Operating Margin Ttm:0.4%
Net Margin Ttm:-92.1%

Yield Metrics (2)

Earnings Yield:-$318.18
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-11.3%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-5.1%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-15.4%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.91x
Quick Ratio:0.91x
Cash Ratio:0.01x

Leverage Analysis (3)

Debt To Equity Ttm:13.01x
Debt-to-Equity Ratio:13.01x
Debt To Ebitda:521.64x

Coverage Ratios (2)

Interest Coverage Ratio:0.14x
Times Interest Earned:0.14

Capital Structure (4)

Working Capital:-2,314,693.00
Cash And Cash Equivalents:217,654.00
Long Term Debt:$22.73M
Net Debt:$24.38M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $10.21M
Linear Growth: -5.1%
📊 Click to view full CDIX Revenue analysis & methodology →
Cost Of Revenue Ttm:$4.04M

Profitability Breakdown (2)

Gross profit TTM: $6.17M
Linear Growth: -8.3%
📊 Click to view full CDIX Gross Profit analysis & methodology →
Operating income TTM: $44.78K
Linear Growth: -15.4%
📊 Click to view full CDIX Operating Income analysis & methodology →

Bottom Line Performance (3)

-$9.40M
Income Before Tax:-$5.75M
Ebitda Ttm:47,154.00

Operating Expenses (5)

Operating Expenses:7,279,652.00
R And D Expense:0.00
Sga Expense:5,589,172.00
Income Tax Expense:$0.00
Interest Expense:8,041,786.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:258.8%
Ebitda Margin:0.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$30.68M
Current Assets:$24.30M
Ppe Net:63,858.00
Goodwill:5,666,608.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:28,925,543.00
Current Liabilities:26,610,571.00
Long Term Debt:$22.73M
Short Term Debt:$1.87M

Equity & Capital (3)

Equity:$1.76M
Retained Earnings:-$85.62M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:23,725,621.00
Inventory:0.00
Accounts Payable:1,517,782.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:366,939.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.38M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$381.70K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$2.19K

Non-Cash Items (1)

Depreciation Amortization Ttm:2,370.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.26
-$1.26
Earnings Per Share Ttm:-$0.62

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.67
Operating Cash Flow Per Share:-$0.19

Book Value & Capital (2)

Book Value Per Share:$0.11
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.35x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:0.43x
Days Sales Outstanding Ttm:847.94

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:137.06
Cash Conversion Cycle:-288.12
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-5.1%
Operating Income Growth Rate (Linear):-15.4%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-8.3%
Book Value Growth Rate (Linear):5.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:CDIX
Company Name:CARDIFF LEXINGTON CORPORATION
Sector:Healthcare
Industry:Services-Offices & Clinics of Doctors of Medicine
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:15.27M
Shares Outstanding Basic:15.27M
Shares Outstanding Diluted:15.27M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 10:57:37 UTC
Data Timestamp:2026-08-21T02:35:00.447723
Scroll to Top